Postal questionnaires were sent to 308 clinicians in the UK (general practitioners, obstetricians, clinical geneticists, neurologists, paediatricians, and paediatric neurologists) to assess their knowledge of, and attitudes to, the prenatal diagnosis of three common single gene disorders, Huntington's disease (HD), cystic fibrosis (CF), and Duchenne muscular dystrophy (DMD). Replies received numbered 213, a response rate of 69%. Overall, 95% of responding clinicians thought that offering prenatal diagnosis for the three test conditions was often or always appropriate. There was a correlation between the clinicians' estimates of life expectancy and their willingness to offer prenatal diagnosis (p < 0-01). Among the non-geneticists questioned, fewer than 50% of general practitioners answered correctly regarding the availability of prenatal tests.
Three of the commonest single gene disorders in the UK are Huntington's disease (HD), cystic fibrosis (CF), and Duchenne muscular dystrophy (DMD). DNA probes closely linked to the genes for these diseases are now available, and more recently probes have been developed that identify intragenic defects in most subjects with CF' and DMD.' Possession of these probes, together with the innovation of chorion villus sampling (CVS), enables prenatal diagnosis to be implemented in some pregnancies at high risk for a single gene disorder as early as 8 to 10 weeks' gestation.3 In a recent review of the work of a single regional molecular genetics laboratory, 132 prenatal diagnoses had been completed using DNA probes and CVS for these three conditions, and demand was increasing.4 How- Professional reticence in offering prenatal diagnosis may have the practical effect of blocking access even when the pregnant woman is fully informed about her options.5 A survey of more than 2800 families referred for DNA testing4 confirmed that most patients were referred by paediatricians, general practitioners, obstetricians, and neurologists.4 These specialties, and clinical geneticists, were surveyed to assess clinicians' knowledge of the availability of prenatal diagnosis for HD, CF, and DMD, their attitudes to selective termination of pregnancy in the event of a positive prenatal diagnosis for each of the three test conditions, and the extent to which their assessments of the severity of these diseases influenced their willingness to offer to arrange prenatal diagnosis. weeks of pregnancy in some families." Question 3. "I was aware/unaware that affected families should preferably be referred before a pregnancy occurs, so that DNA from family members can be examined to determine Firth, Lindenbaum Table 4 Knowledge of availability of prenatal diagnosis using DNA probes, and awareness that diagnosis involves chorionic villus sampling (CVS) at 8 to 10 weeks. This section of the questionnaire was designed to assess clinicians' knowledge of the availability and optimal timing of tests used in prenatal diagnosis for the three test diseases HD, CF, and DMD. Table 4 indicates great variability in awareness among the different clinical specialties, awareness being greatest among clinicians caring for affected persons, intermediate among obstetricians, and lowest (less than 50% for each of the three test diseases) among general practitioners. The general practitioner is often the first clinician to be notified when a pregnancy occurs, and it is a matter of concern that over a quarter of general practitioners were unaware that first trimester CVS could be used in the prenatal diagnosis of the test conditions. The final question in this section dealt with the practicalities of offering prenatal testing in families where the testing is based on linkage rather than direct analysis of a mutation. Since the questionnaire was written, major technical advances have occurred, and deletions can now be detected in over 50% of boys with DMD, and the AF508 mutation can be detected in 70% of subjects heterozygous for cystic fibrosis. Nevertheless, until such advances enable direct mutation detection in nearly all affected subjects, the principle of preconceptual referral still applies. Table 5 shows that the majority of clinicians were aware of the desirability of referral before a pregnancy, with GPs being the least informed group (58%).
Study design
ATTITUDES TO OFFERING PRENATAL DIAGNOSIS Table 1 shows there was a highly consistent response among clinicians from the different specialties, most believing that it is always or often appropriate to offer prenatal diagnosis in pregnancies at risk for the three test conditions (averaged response for HD was 4 5, averaged response for CF and for DMD was 4-8). These results showed some correlation with clinicians' estimates of life expectancy for the three diseases (figure, r = -0-825, p < 0-01), but The smooth running of a prenatal diagnosis service based on first trimester sampling and analysis requires that referral be made very early in pregnancy, preferably at 6 to 8 weeks' gestation, and if linkage techniques are to be used the family should have been 'worked up' in the laboratory before the pregnancy. Our study highlights two important problem areas: more than a quarter of GPs sampled were unaware of the possibility of first trimester tests, and nearly a half were unaware of the need for previous referral of patients. More encouraging were the results from specialists caring for patients affected by the test diseases; overall they showed a high level of knowledge regarding availability of and optimal timing for prenatal diagnosis using molecular genetics techniques. This is perhaps most likely to ensure success in implementing prenatal diagnosis in autosomal recessive conditions such as cystic fibrosis, where most of the recurrence risk is borne by the immediate family, but less certain to ensure appropriate referral for X linked diseases, such as Duchenne muscular dystrophy (where carrier females may be distanced both spatially and temporally from the affected male), or late onset autosomal disorders such as Huntington's disease, where regular involvement of a specialist clinician, neurologist, or psychiatrist, may not take place until after the birth of the patient's children or grandchildren. In these latter circumstances, relatives with pregnancies at risk for the disorder will be dependent either on the astuteness of their general practitioner in recognising the genetic risk and making the appropriate referral, or on the efficient running of a genetic register.
This study indicates a need for initiatives to disseminate knowledge of new techniques among general practitioners. This need may be greater than that defined by the study results, since it is probable that those clinicians completing the questionnaire were more informed, or had more experience of the subject matter, than those choosing not to reply. The study also corroborates a recent finding that threequarters of a sample of Scottish general practitioners were unfamiliar with the details of DNA based linkage analysis.9
Our overall conclusion is that the introduction of first trimester prenatal diagnosis for single gene disorders based on molecular genetics techniques is acceptable to the great majority of UK clinicians practising in specialties likely to use it.
